Apollomics Inc. Form 6-K Summary
Business Context and Reporting Period
Apollomics Inc., a foreign private issuer that files annual reports on Form 20-F, filed this Form 6-K for March 2024. The filing reports a management change announced on March 4, 2024.
Material Change
Apollomics appointed Matthew Plunkett, Ph.D. as Chief Financial Officer, effective immediately. Dr. Plunkett has more than 25 years of strategic and financial experience in the biopharmaceutical sector and previously served as CFO of Aeovian Pharmaceuticals, Imago Biosciences and Nkarta Therapeutics.
His prior experience included leading Nasdaq initial public offering efforts at Imago Biosciences and Nkarta Therapeutics. Imago Biosciences was subsequently acquired by Merck.
Financial Metrics, Outlook and Risks
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance, operating outlook or other financial metrics. It also does not disclose new risks, contingencies or unusual financial items.
The company furnished a press release regarding the appointment as Exhibit 99.1. The press release is not deemed filed for purposes of Section 18 of the Exchange Act, although the Form 6-K information concerning Dr. Plunkett’s appointment is filed and incorporated by reference into applicable registration statements.
Important Facts to Verify
- Confirm the effective date and scope of Matthew Plunkett’s CFO appointment.
- Review any subsequent filings for changes in executive responsibilities, compensation or employment terms.
- Assess whether the new CFO’s capital markets experience affects financing, IPO-related or strategic plans.
- Obtain the company’s latest financial statements and subsequent filings, as this Form 6-K contains no financial results or liquidity information.